Damora Therapeutics Reports Q3 GAAP EPS of -$0.40, Exceeding Estimates
Damora Therapeutics (NASDAQ: DMRA) reported third-quarter GAAP earnings per share of -$0.40, surpassing analyst expectations by $0.07. Despite the net loss, the company's financial position remains robust following its recent reporting period. As of September 30, 2026, the company held approximately $528.5 million in cash, cash equivalents, and marketable securities. Management indicated that these liquid assets are expected to be sufficient to fund ongoing operations for the foreseeable future.
